Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Gets EU Okay For Diabetic Macular Edema
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
